Akari TX

NEW YORK and LONDON, May 12, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that …

[Read more...] about Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Guillain Barré Syndrome

NEW YORK and LONDON,and FREISING, Germany, April 14, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, …

[Read more...] about Akari Therapeutics Plc and XL-protein GmbH Sign License Agreement to Develop a Long Acting Version of Coversin Using PASylation® Technology

NEW YORK and LONDON, March 31, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today …

[Read more...] about Akari Therapeutics Announces Positive Preliminary Results from First PNH Patient Treated With Coversin

NEW YORK and LONDON, March 1, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that …

[Read more...] about Akari Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference

NEW YORK and LONDON, February 17, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today …

[Read more...] about Akari Therapeutics to Participate in the 2016 SunTrust Robinson Humphrey Orphan Drug Day